EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?

Takahiro Karasaki

AME Clinical Trials Review · 2026-06 · 4 · 24-24

DOI: 10.21037/actr-25-107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Takahiro Karasaki.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Karasaki, T. (2026). Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?. AME Clinical Trials Review, 4, 24-24. https://doi.org/10.21037/actr-25-107

Vancouver

Karasaki T. Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?. AME Clinical Trials Review. 2026;4:24-24. doi:10.21037/actr-25-107

BibTeX
@article{Karasaki2026,
  author = {Karasaki, Takahiro},
  title = {Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {24--24},
  doi = {10.21037/actr-25-107}
}
Kostenlos starten →